It’s a bit cryptic …
From the quarterly on the 30th Jan it was said ….
“There were preliminary signs of efficacy from the 14 patients dosed in the Phase 1b trial.”
From today’s Ann …
Of these fourteen patients seven (7) patients remained on trial for >6 months, with two (2)
patients being on trial for more than 10 months.
Six (6) patients have now recorded a partial response as best response, with the remaining
eight (8) recording stable disease.
6 and 8 presumably that’s the 14 patients in question from 1b trail
No mention of any deaths …
These response rates are substantially higher than predicted from historical studies of
gemcitabine and Abraxane treatment alone.
And importantly, … Three (3) patients remain on trial from the Phase 1b cohort.
.
- Forums
- ASX - By Stock
- Ann: Update on ACCENT Trial in Pancreatic Cancer
It’s a bit cryptic … From the quarterly on the 30th Jan it was...
-
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATX (ASX) to my watchlist
(20min delay)
|
|||||
Last
12.5¢ |
Change
-0.005(3.85%) |
Mkt cap ! $34.27M |
Open | High | Low | Value | Volume |
13.0¢ | 13.0¢ | 12.0¢ | $120.7K | 983.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 279677 | 12.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
12.5¢ | 16317 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 229677 | 0.120 |
2 | 349506 | 0.115 |
3 | 33787 | 0.110 |
5 | 289600 | 0.105 |
13 | 487000 | 0.100 |
Price($) | Vol. | No. |
---|---|---|
0.125 | 16317 | 1 |
0.130 | 82439 | 1 |
0.135 | 25000 | 1 |
0.140 | 132730 | 3 |
0.145 | 120000 | 3 |
Last trade - 15.44pm 23/08/2024 (20 minute delay) ? |
Featured News
ATX (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online